Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2010, Article ID 515136, 10 pages
http://dx.doi.org/10.1155/2010/515136
Review Article

Cytokines in the Progression of Pancreatic β-Cell Dysfunction

Department of Physiology and Pathophysiology, Peking University Diabetes Center, Peking University Health Science Center, Beijing 100191, China

Received 28 April 2010; Revised 5 August 2010; Accepted 7 October 2010

Academic Editor: Robert R. Henry

Copyright © 2010 Chunjiong Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Kawasaki , N. Abiru, and K. Eguchi, “Prevention of type 1 diabetes: from the view point of β cell damage,” Diabetes Research and Clinical Practice, vol. 66, supplement 1, pp. S27–S32, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Stumvoll, B. J. Goldstein, and T. W. Van Haeften, “Type 2 diabetes: principles of pathogenesis and therapy,” The Lancet, vol. 365, no. 9467, pp. 1333–1346, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. A. K. Andersson, M. Flodström, and S. Sandler, “Cytokine-induced inhibition of insulin release from mouse pancreatic β-cells deficient in inducible nitric oxide synthase,” Biochemical and Biophysical Research Communications, vol. 281, no. 2, pp. 396–403, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman, “Positional cloning of the mouse obese gene and its human homologue,” Nature, vol. 372, no. 6505, pp. 425–432, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. R. S. Ahima, “Adipose tissue as an endocrine organ,” Obesity, vol. 14, supplement 5, pp. 242S–249S, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Bassols, F. J. Ortega, J. M. Moreno-Navarrete, B. Peral, W. Ricart, and J.-M. Fernández-Real, “Study of the proinflammatory role of human differentiated omental adipocytes,” Journal of Cellular Biochemistry, vol. 107, no. 6, pp. 1107–1117, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. X. Cao, Z. Gao, C. E. Robert et al., “Pancreatic-derived factor (FAM3B), a novel islet cytokine, induces apoptosis of insulin-secreting β-cells,” Diabetes, vol. 52, no. 9, pp. 2296–2303, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. X. Cao, J. Yang, B. R. Burkhardt et al., “Effects of overexpression of pancreatic derived factor (FAM3B) in isolated mouse islets and insulin-secreting βTC3 cells,” American Journal of Physiology, vol. 289, no. 4, pp. E543–E550, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Yang, C. E. Robert, B. R. Burkhardt et al., “Mechanisms of glucose-induced secretion of pancreatic-derived factor (PANDER or FAM3B) in pancreatic β-cells,” Diabetes, vol. 54, no. 11, pp. 3217–3228, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Y. Donath, M. Böni-Schnetzler, H. Ellingsgaard, P. A. Halban, and J. A. Ehses, “Cytokine production by islets in health and diabetes: cellular origin, regulation and function,” Trends in Endocrinology and Metabolism, vol. 21, no. 5, pp. 261–267, 2010. View at Publisher · View at Google Scholar
  11. Y. Zhu, G. Xu, A. Patel et al., “Cloning, expression, and initial characterization of a novel cytokine-like gene family,” Genomics, vol. 80, no. 2, pp. 144–150, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Matsuzawa, “The metabolic syndrome and adipocytokines,” FEBS Letters, vol. 580, no. 12, pp. 2917–2921, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Zhang and K.-H. Kim, “TNF-α inhibits glucose-induced insulin secretion in a pancreatic β-cell line (INS-1),” FEBS Letters, vol. 377, no. 2, pp. 237–239, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Kiely, N. H. McClenaghan, P. R. Flatt, and P. Newsholme, “Pro-inflammatory cytokines increase glucose, alanine and triacylglycerol utilization but inhibit insulin secretion in a clonal pancreatic β-cell line,” The Journal of Endocrinology, vol. 195, no. 1, pp. 113–123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Yang, Y. Chi, B. R. Burkhardt, Y. Guan, and B. A. Wolf, “Leucine metabolism in regulation of insulin secretion from pancreatic beta cells,” Nutrition Reviews, vol. 68, no. 5, pp. 270–279, 2010. View at Publisher · View at Google Scholar
  16. H. A. Arafat, A. K. Katakam, G. Chipitsyna et al., “Osteopontin protects the islets and β-cells from interleukin-1 β-mediated cytotoxicity through negative feedback regulation of nitric oxide,” Endocrinology, vol. 148, no. 2, pp. 575–584, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Kwon, J. A. Corbett, S. Hauser, J. R. Hill, J. Turk, and M. L. McDaniel, “Evidence for involvement of the proteasome complex (26S) and NFκB in IL-1β-induced nitric oxide and prostaglandin production by rat islets and RINm5F cells,” Diabetes, vol. 47, no. 4, pp. 583–591, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Ortis, A. K. Cardozo, D. Crispim, J. Störling, T. Mandrup-Poulsen, and D. L. Eizirik, “Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained, and nonoscillatory nuclear factor-κB activation,” Molecular Endocrinology, vol. 20, no. 8, pp. 1867–1879, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Larsen, J. Størling, M. Darville et al., “Extracellular signal-regulated kinase is essential for interleukin-1- induced and nuclear factor κB-mediated gene expression in insulin-producing INS-1E cells,” Diabetologia, vol. 48, no. 12, pp. 2582–2590, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Papaccio, A. Graziano, R. D'Aquino, S. Valiante, and F. Naro, “A biphasic role of nuclear transcription factor (NF)-κB in the islet β-cell apoptosis induced by interleukin (IL)-1β,” Journal of Cellular Physiology, vol. 204, no. 1, pp. 124–130, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. E.-K. Kim, M.-Y. Song, T.-O. Hwang et al., “Radix clematidis extract protects against cytokine-and streptozotocin-induced β-cell damage by suppressing the NF-κB pathway,” International Journal of Molecular Medicine, vol. 22, no. 3, pp. 349–356, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M.-Y. Song, E.-K. Kim, W.-S. Moon et al., “Sulforaphane protects against cytokine- and streptozotocin-induced β-cell damage by suppressing the NF-κB pathway,” Toxicology and Applied Pharmacology, vol. 235, no. 1, pp. 57–67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Lv, M.-Y. Song, E.-K. Kim, J.-W. Park, K.-B. Kwon, and B.-H. Park, “Guggulsterone, a plant sterol, inhibits NF-κB activation and protects pancreatic β cells from cytokine toxicity,” Molecular and Cellular Endocrinology, vol. 289, no. 1-2, pp. 49–59, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. A. K. Azevedo-Martins, S. Lortz, S. Lenzen, R. Curi, D. L. Eizirik, and M. Tiedge, “Improvement of the mitochondrial antioxidant defense status prevents cytokine-induced nuclear factor-κB activation in insulin-producing cells,” Diabetes, vol. 52, no. 1, pp. 93–101, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. J. G. Mabley, G. Haskó, L. Liaudet et al., “NFκB1 (p50)-deficient mice are not susceptible to multiple low-dose streptozotocin-induced diabetes,” The Journal of Endocrinology, vol. 173, no. 3, pp. 457–464, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. E. B. Hammar, J.-C. Irminger, K. Rickenbach et al., “Activation of NF-κB by extracellular matrix is involved in spreading and glucose-stimulated insulin secretion of pancreatic beta cells,” The Journal of Biological Chemistry, vol. 280, no. 34, pp. 30630–30637, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Liu, D. Pavlovic, M.-C. Chen, M. Flodström, S. Sandler, and D. L. Eizirik, “Cytokines induce apoptosis in β-cells isolated from mice lacking the inducible isoform of nitric oxide synthase (iNOS-/-),” Diabetes, vol. 49, no. 7, pp. 1116–1122, 2000. View at Google Scholar · View at Scopus
  28. A. K. Andersson, A. Börjesson, J. Sandgren, and S. Sandler, “Cytokines affect PDX-1 expression, insulin and proinsulin secretion from iNOS deficient murine islets,” Molecular and Cellular Endocrinology, vol. 240, no. 1-2, pp. 50–57, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. Q. Wang, H. Zhang, B. Zhao, and H. Fei, “IL-1β caused pancreatic β-cells apoptosis is mediated in part by endoplasmic reticulum stress via the induction of endoplasmic reticulum Ca2+ release through the c-Jun N-terminal kinase pathway,” Molecular and Cellular Biochemistry, vol. 324, no. 1-2, pp. 183–190, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. A. K. Cardozo, F. Ortis, J. Storling et al., “Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic β-cells,” Diabetes, vol. 54, no. 2, pp. 452–461, 2005. View at Publisher · View at Google Scholar
  31. E. N. Gurzov, F. Ortis, D. A. Cunha et al., “Signaling by IL-1β+IFN-γ and ER stress converge on DP5/Hrk activation: a novel mechanism for pancreatic β-cell apoptosis,” Cell Death and Differentiation, vol. 16, no. 11, pp. 1539–1550, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Maedler, P. Sergeev, F. Ris et al., “Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets,” The Journal of Clinical Investigation, vol. 110, no. 6, pp. 851–860, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Böni-Schnetzler, J. Thorne, G. Parnaud et al., “Increased interleukin (IL)-1β messenger ribonucleic acid expression in β-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 10, pp. 4065–4074, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Welsh, M. Cnop, I. Kharroubi et al., “Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets?” Diabetes, vol. 54, no. 11, pp. 3238–3244, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Téllez, M. Montolio, M. Biarnés, E. Castanño, J. Soler, and E. Montanya, “Adenoviral overexpression of interleukin-1 receptor antagonist protein increases β-cell replication in rat pancreatic islets,” Gene Therapy, vol. 12, no. 2, pp. 120–128, 2005. View at Publisher · View at Google Scholar
  36. N. S. Sauter, F. T. Schulthess, R. Galasso, L. W. Castellani, and K. Maedler, “The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia,” Endocrinology, vol. 149, no. 5, pp. 2208–2218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. O. Osborn, S. E. Brownell, M. Sanchez-Alavez, D. Salomon, H. Gram, and T. Bartfai, “Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity,” Cytokine, vol. 44, no. 1, pp. 141–148, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. J. A. Ehses, G. Lacraz, M.-H. Giroix et al., “IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 13998–14003, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Lacraz, M.-H. Giroix, N. Kassis et al., “Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat,” PLoS ONE, vol. 4, no. 9, Article ID e6963, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Giannoukakis, W. A. Rudert, S. C. Ghivizzani et al., “Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-lβ-induced β-cell impairment and activation of islet cell apoptosis in vitro,” Diabetes, vol. 48, no. 9, pp. 1730–1736, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Zeender, K. Maedler, D. Bosco, T. Berney, M. Y. Donath, and P. A. Halban, “Pioglitazone and sodium salicylate protect human β-cells against apoptosis and impaired function induced by glucose and interleukin-1β,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 10, pp. 5059–5066, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. C. M. Larsen, M. Faulenbach, A. Vaag et al., “Interleukin-1-receptor antagonist in type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 356, no. 15, pp. 1517–1526, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Y. Donath and T. Mandrup-Poulsen, “The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus,” Nature Clinical Practice Endocrinology and Metabolism, vol. 4, no. 5, pp. 240–241, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Suk, S. Kim, Y.-H. Kim et al., “IFN-γ/TNF-α synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic/β cell death,” Journal of Immunology, vol. 166, no. 7, pp. 4481–4489, 2001. View at Google Scholar · View at Scopus
  45. S. K. Hun, S. Kim, and M.-S. Lee, “IFN-γ sensitizes MIN6N8 insulinoma cells to TNF-α-induced apoptosis by inhibiting NF-κB-mediated XIAP upregulation,” Biochemical and Biophysical Research Communications, vol. 336, no. 3, pp. 847–853, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. I. Chang, N. Cho, S. Kim et al., “Role of calcium in pancreatic islet cell death by IFN-γ/TNF-α,” Journal of Immunology, vol. 172, no. 11, pp. 7008–7014, 2004. View at Google Scholar · View at Scopus
  47. W. H. Kim, J. W. Lee, B. Gao, and M. H. Jung, “Synergistic activation of JNK/SAPK induced by TNF-α and IFN-γ: apoptosis of pancreatic β-cells via the p53 and ROS pathway,” Cellular Signalling, vol. 17, no. 12, pp. 1516–1532, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. M. M. W. Chong, H. E. Thomas, and T. W. H. Kay, “Suppressor of cytokine signaling-1 regulates the sensitivity of pancreatic β cells to tumor necrosis factor,” The Journal of Biological Chemistry, vol. 277, no. 31, pp. 27945–27952, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Sekine, T. Ishikawa, T. Okazaki, M. Hayashi, C. B. Wollheim, and T. Fujita, “Synergistic activation of NF-κB and inducible isoform of nitric oxide synthase induction by interferon-γ and tumor necrosis factor-α in INS-1 cells,” Journal of Cellular Physiology, vol. 184, no. 1, pp. 46–57, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Chen, A. Ren, S. Hu, W. Mo, X. Xin, and W. Jia, “The significance of tumor necrosis factor-α in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment,” Diabetes Research and Clinical Practice, vol. 75, no. 3, pp. 327–332, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. I. Sadaf Farooqi and S. O'Rahilly, “Leptin: a pivotal regulator of human energy homeostasis,” American Journal of Clinical Nutrition, vol. 89, no. 3, pp. 980S–984S, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. J. M. Friedman and J. L. Halaas, “Leptin and the regulation of body weight in mammals,” Nature, vol. 395, no. 6704, pp. 763–770, 1998. View at Publisher · View at Google Scholar · View at Scopus
  53. T. J. Kieffer, R. S. Heller, and J. F. Habener, “Leptin receptors expressed on pancreatic β-cells,” Biochemical and Biophysical Research Communications, vol. 224, no. 2, pp. 522–527, 1996. View at Publisher · View at Google Scholar · View at Scopus
  54. S. D. Covey, R. D. Wideman, C. McDonald et al., “The pancreatic β cell is a key site for mediating the effects of leptin on glucose homeostasis,” Cell Metabolism, vol. 4, no. 4, pp. 291–302, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Morioka, E. Asilmaz, J. Hu et al., “Disruption of leptin receptor expression in the pancreas directly affects β cell growth and function in mice,” The Journal of Clinical Investigation, vol. 117, no. 10, pp. 2860–2868, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. X.-D. Wang, J. Liu, J.-C. Yang, W.-Q. Chen, and J.-G. Tang, “Mice body weight gain is prevented after naked human leptin cDNA transfer into skeletal muscle by electroporation,” Journal of Gene Medicine, vol. 5, no. 11, pp. 966–976, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. W. S. Chen, X.-D. Peng, Y. Wang et al., “Leptin deficiency and beta-cell dysfunction underlie type 2 diabetes in compound Akt knockout mice,” Molecular and Cellular Biology, vol. 29, no. 11, pp. 3151–3162, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Okuya, K. Tanabe, Y. Tanizawa, and Y. Oka, “Leptin increases the viability of isolated rat pancreatic islets by suppressing apoptosis,” Endocrinology, vol. 142, no. 11, pp. 4827–4830, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Shimabukuro, M.-Y. Wang, Y.-T. Zhou, C. B. Newgard, and R. H. Unger, “Protection against lipoapoptosis of β cells through leptin-dependent maintenance of Bcl-2 expression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 16, pp. 9558–9561, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. J. E. P. Brown and S. J. Dunmore, “Leptin decreases apoptosis and alters BCL-2: bax ratio in clonal rodent pancreatic beta-cells,” Diabetes/Metabolism Research and Reviews, vol. 23, no. 6, pp. 497–502, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. C. M. Taniguchi, B. Emanuelli, and C. R. Kahn, “Critical nodes in signalling pathways: insights into insulin action,” Nature Reviews Molecular Cell Biology, vol. 7, no. 2, pp. 85–96, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. N. Kubota, Y. Terauchi, K. Tobe et al., “Insulin receptor substrate 2 plays a crucial role in β cells and the hypothalamus,” The Journal of Clinical Investigation, vol. 114, no. 7, pp. 917–927, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. P. R. Huypens, “Leptin and adiponectin regulate compensatory beta cell growth in accordance to overweight,” Medical Hypotheses, vol. 68, no. 5, pp. 1134–1137, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Harvey, F. McKenna, P. S. Herson, D. Spanswick, and M. L. J. Ashford, “Leptin activates ATP-sensitive potassium channels in the rat insulin-secreting cell line, CRI-G1,” Journal of Physiology, vol. 504, no. 3, pp. 527–535, 1997. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Z. Zhao, K. E. Bornfeldt, and J. A. Beavo, “Leptin inhibits insulin secretion by activation of phosphodiesterase 3B,” The Journal of Clinical Investigation, vol. 102, no. 5, pp. 869–873, 1998. View at Google Scholar · View at Scopus
  66. K. Laubner, T. J. Kieffer, N. T. Lam, X. Niu, F. Jakob, and J. Seufert, “Inhibition of preproinsulin gene expression by leptin induction of suppressor of cytokine signaling 3 in pancreatic β-cells,” Diabetes, vol. 54, no. 12, pp. 3410–3417, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Seufert, “Leptin effects on pancreatic β-cell gene expression and function,” Diabetes, vol. 53, no. 1, pp. S152–S158, 2004. View at Google Scholar · View at Scopus
  68. Y. Benomar, N. Rideau, S. Crochet, M. Derouet, and M. Taouis, “Leptin fully suppresses acetylcholine-induced insulin secretion and is reversed by tolbutamide in isolated perfused chicken pancreas,” Hormone and Metabolic Research, vol. 35, pp. 81–85, 2003. View at Google Scholar
  69. P. Hekerman, J. Zeidler, S. Korfmacher et al., “Leptin induces inflammation-related genes in RINm5F insulinoma cells,” BMC Molecular Biology, vol. 8, article 41, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. S. L. Gray, C. Donald, A. Jetha, S. D. Covey, and T. J. Kieffer, “Hyperinsulinemia precedes insulin resistance in mice lacking pancreatic {beta}-cell leptin signaling,” Endocrinology, vol. 151, no. 9, pp. 4178–4186, 2010. View at Google Scholar
  71. S. Park, I. S. Ahn, and D. S. Kim, “Central infusion of leptin improves insulin resistance and suppresses β-cell function, but not β-cell mass, primarily through the sympathetic nervous system in a type 2 diabetic rat model,” Life Sciences, vol. 86, no. 23-24, pp. 854–862, 2010. View at Publisher · View at Google Scholar
  72. M. Guldstrand, B. Ahrén, and U. Adamson, “Improved β-cell function after standardized weight reduction in severely obese subjects,” American Journal of Physiology, vol. 284, no. 3, pp. E557–E565, 2003. View at Google Scholar · View at Scopus
  73. K. Maedler, P. Sergeev, J. A. Ehses et al., “Leptin modulates β cell expression of IL-1 receptor antagonist and release of IL-1β in human islets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 21, pp. 8138–8143, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. K. Maedler, F. T. Schulthess, C. Bielman et al., “Glucose and leptin induce apoptosis in human β-cells and impair glucose-stimulated insulin secretion through activation of c-Jun N-terminal kinases,” The FASEB Journal, vol. 22, no. 6, pp. 1905–1913, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. J. E. P. Brown, S. Thomas, J. E. Digby, and S. J. Dunmore, “Glucose induces and leptin decreases expression of uncoupling protein-2 mRNA in human islets,” FEBS Letters, vol. 513, no. 2-3, pp. 189–192, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. R. Lupi, P. Marchetti, M. Maffei et al., “Effects of acute or prolonged exposure to human leptin on isolated human islet function,” Biochemical and Biophysical Research Communications, vol. 256, no. 3, pp. 637–641, 1999. View at Publisher · View at Google Scholar · View at Scopus
  77. C. M. Steppan, S. T. Bailey, S. Bhat et al., “The hormone resistin links obesity to diabetes,” Nature, vol. 409, no. 6818, pp. 307–312, 2001. View at Publisher · View at Google Scholar · View at Scopus
  78. T. Tomaru, D. J. Steger, M. I. Lefterova, M. Schupp, and M. A. Lazar, “Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor γ and CCAAT/enhancer-binding proteins,” The Journal of Biological Chemistry, vol. 284, no. 10, pp. 6116–6125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. J. E. P. Brown, D. J. Onyango, and S. J. Dunmore, “Resistin down-regulates insulin receptor expression, and modulates cell viability in rodent pancreatic beta-cells,” FEBS Letters, vol. 581, no. 17, pp. 3273–3276, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. C.-L. Gao, D.-Y. Zhao, J. Qiu et al., “Resistin induces rat insulinoma cell RINm5F apoptosis,” Molecular Biology Reports, vol. 73, no. 7, pp. 1703–1708, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Nakata, T. Okada, K. Ozawa, and T. Yada, “Resistin induces insulin resistance in pancreatic islets to impair glucose-induced insulin release,” Biochemical and Biophysical Research Communications, vol. 353, no. 4, pp. 1046–1051, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. A. H. Minn, N. B. Patterson, S. Pack et al., “Resistin is expressed in pancreatic islets,” Biochemical and Biophysical Research Communications, vol. 310, no. 2, pp. 641–645, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. J. Yang, D. Zhang, J. Li, X. Zhang, F. Fan, and Y. Guan, “Role of PPARγ in renoprotection in type 2 diabetes: molecular mechanisms and therapeutic potential,” Clinical Science, vol. 116, no. 1, pp. 17–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. T. Kadowaki and T. Yamauchi, “Adiponectin and adiponectin receptors,” Endocrine Reviews, vol. 26, no. 3, pp. 439–451, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Guerre-Millo, “Adiponectin: an update,” Diabetes and Metabolism, vol. 34, no. 1, pp. 12–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. B. S. Nayak, D. Ramsingh, S. Gooding et al., “lasma adiponectin levels are related to obesity, inflammation, blood lipids and insulin in type 2 diabetic and non-diabetic Trinidadians,” Prim Care Diabetes, vol. 4, no. 3, pp. 187–192, 2010. View at Google Scholar
  87. R. Retnakaran, Y. Qi, P. W. Connelly, M. Sermer, A. J. Hanley, and B. Zinman, “Low adiponectin concentration during pregnancy predicts postpartum insulin resistance, beta cell dysfunction and fasting glycaemia,” Diabetologia, vol. 53, no. 2, pp. 268–276, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. A. H. Xiang, M. Kawakubo, E. Trigo, S. L. Kjos, and T. A. Buchanan, “Declining β-cell compensation for insulin resistance in hispanic women with recent gestational diabetes mellitus: association with changes in weight, adiponectin, and C-reactive protein,” Diabetes Care, vol. 33, no. 2, pp. 396–401, 2010. View at Publisher · View at Google Scholar
  89. W.-Y. So, P. C. Tong, G. T. Ko et al., “Low plasma adiponectin level, white blood cell count and Helicobacter pylori titre independently predict abnormal pancreatic β-cell function,” Diabetes Research and Clinical Practice, vol. 86, no. 2, pp. 89–95, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. I. Kharroubi, J. Rasschaert, D. L. Eizirik, and M. Cnop, “Expression of adiponectin receptors in pancreatic β cells,” Biochemical and Biophysical Research Communications, vol. 312, no. 4, pp. 1118–1122, 2003. View at Publisher · View at Google Scholar · View at Scopus
  91. T. W. Jung, M. W. Lee, Y. J. Lee et al., “Regulation of adiponectin receptor 2 expression via PPAR-α in NIT-1 cells,” Endocrine Journal, vol. 56, no. 3, pp. 377–382, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. T. E. Wade, A. Mathur, D. Lu, D. A. Swartz-Basile, H. A. Pitt, and N. J. Zyromski, “Adiponectin Receptor-1 Expression Is Decreased in the Pancreas of Obese Mice,” Journal of Surgical Research, vol. 154, no. 1, pp. 78–84, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. I. Rakatzi, H. Mueller, O. Ritzeler, N. Tennagels, and J. Eckel, “Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1,” Diabetologia, vol. 47, no. 2, pp. 249–258, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. P. Lin, L. Chen, D. Li et al., “Adiponectin reduces glucotoxicity-induced apoptosis of INS-1 rat insulin-secreting cells on a microfluidic chip,” Tohoku Journal of Experimental Medicine, vol. 217, no. 1, pp. 59–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. W. Gu, X. Li, C. Liu et al., “Globular adiponectin augments insulin secretion from pancreatic islet β cells at high glucose concentrations,” Endocrine, vol. 30, no. 2, pp. 217–221, 2006. View at Publisher · View at Google Scholar · View at Scopus
  96. M. S. Winzell, R. Nogueiras, C. Dieguez, and B. Ahrén, “Dual action of adiponectin on insulin secretion in insulin-resistant mice,” Biochemical and Biophysical Research Communications, vol. 321, no. 1, pp. 154–160, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. J. E.P. Brown, A. C. Conner, J. E. Digby et al., “Regulation of beta-cell viability and gene expression by distinct agonist fragments of adiponectin,” Peptides, vol. 31, no. 5, pp. 944–949, 2010. View at Publisher · View at Google Scholar
  98. K. Staiger, N. Stefan, H. Staiger et al., “Adiponectin is functionally active in human islets but does not affect insulin secretory function or β-cell lipoapoptosis,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 12, pp. 6707–6713, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. A. Fukuhara, M. Matsuda, M. Nishizawa et al., “Visfatin: a protein secreted by visceral fat that Mimics the effects of insulin,” Science, vol. 307, no. 5708, pp. 426–430, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. H. Xie, S.-Y. Tang, X.-H. Luo et al., “Insulin-like effects of visfatin on human osteoblasts,” Calcified Tissue International, vol. 80, no. 3, pp. 201–210, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. J. Zhu, M. Schott, R. Liu et al., “Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes,” Hormone and Metabolic Research, vol. 40, no. 11, pp. 801–805, 2008. View at Publisher · View at Google Scholar
  102. Y. S. Kang, H. K. Song, M. H. Lee, G. J. Ko, and D. R. Cha, “Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients,” Diabetes Research and Clinical Practice, vol. 89, no. 2, pp. 141–149, 2010. View at Publisher · View at Google Scholar
  103. J. R. Revollo, A. Körner, K. F. Mills et al., “Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme,” Cell Metabolism, vol. 6, no. 5, pp. 363–375, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. T. Tanaka and Y.-I. Nabeshima, “Nampt/PBEF/Visfatin: a new player in β cell physiology and in metabolic diseases?” Cell Metabolism, vol. 6, no. 5, pp. 341–343, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. E. Wanecq, D. Prévot, and C. Carpéné, “Lack of direct insulin-like action of visfatin/nampt/pbef1 in human adipocytes,” Journal of Physiology and Biochemistry, vol. 65, no. 4, pp. 351–359, 2009. View at Publisher · View at Google Scholar
  106. J. E. P. Brown, D. J. Onyango, M. Ramanjaneya et al., “Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic β-cells,” Journal of Molecular Endocrinology, vol. 44, no. 3, pp. 171–178, 2010. View at Publisher · View at Google Scholar
  107. J. Yang, Z. Gao, C. E. Robert et al., “Structure-function studies of PANDER, an islet specific cytokine inducing cell death of insulin-secreting β cells,” Biochemistry, vol. 44, no. 34, pp. 11342–11352, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. W. Xu, Z. Gao, J. Wu, and B. A. Wolf, “Interferon-γ-induced regulation of the pancreatic derived cytokine FAM3B in islets and insulin-secreting βTC3 cells,” Molecular and Cellular Endocrinology, vol. 240, no. 1-2, pp. 74–81, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. B. R. Burkhardt, M. C. Yang, C. E. Robert et al., “Tissue-specific and glucose-responsive expression of the pancreatic derived factor (PANDER) promoter,” Biochimica et Biophysica Acta, vol. 1730, no. 3, pp. 215–225, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. B. R. Burkhardt, J. R. Cook, R. A. Young, and B. A. Wolf, “PDX-1 interaction and regulation of the Pancreatic Derived Factor (PANDER, FAM3B) promoter,” Biochimica et Biophysica Acta, vol. 1779, no. 10, pp. 645–651, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. J. Yang, C. Wang, J. Li et al., “PANDER binds to the liver cell membrane and inhibits insulin signaling in HepG2 cells,” FEBS Letters, vol. 583, no. 18, pp. 3009–3015, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. S. E. Kahn, D. A. D'Alessio, M. W. Schwartz et al., “Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells,” Diabetes, vol. 39, no. 5, pp. 634–638, 1990. View at Google Scholar · View at Scopus
  113. O. Schmitz, B. Brock, and J. Rungby, “Amylin agonists: a novel approach in the treatment of diabetes,” Diabetes, vol. 53, supplement 3, pp. S233–S238, 2004. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Clark and M. R. Nilsson, “Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?” Diabetologia, vol. 47, no. 2, pp. 157–169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. A. E. Butler, J. Jang, T. Gurlo, M. D. Carty, W. C. Soeller, and P. C. Butler, “Diabetes due to a progressive defect in β-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat): a new model for type 2 diabetes,” Diabetes, vol. 53, no. 6, pp. 1509–1516, 2004. View at Publisher · View at Google Scholar
  116. C. E. Robert-Cooperman, J. R. Carnegie, C. G. Wilson et al., “Targeted disruption of pancreatic-derived factor (PANDER, FAM3B) impairs pancreatic β-cell function,” Diabetes, vol. 59, no. 9, pp. 2209–2218, 2010. View at Publisher · View at Google Scholar
  117. O. Wang, K. Cai, S. Pang et al., “Mechanisms of glucose-induced expression of pancreatic-derived factor in pancreatic β-cells,” Endocrinology, vol. 149, no. 2, pp. 672–680, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. J. R. Carnegie, C. E. Robert-Cooperman, J. Wu, R. A. Young, B. A. Wolf, and B. R. Burkhardt, “Characterization of the expression, localization, and secretion of PANDER in α-cells,” Molecular and Cellular Endocrinology, vol. 325, no. 1-2, pp. 36–45, 2010. View at Publisher · View at Google Scholar
  119. J. Lo, L. E. Bernstein, B. Canavan et al., “Effects of TNF-α neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome,” American Journal of Physiology, vol. 293, no. 1, pp. E102–E109, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. C. Asensio, P. Cettour-Rose, C. Theander-Carrillo, F. Rohner-Jeanrenaud, and P. Muzzin, “Changes in glycemia by leptin administration or high-fat feeding in rodent models of obesity/type 2 diabetes suggest a link between resistin expression and control of glucose homeostasis,” Endocrinology, vol. 145, no. 5, pp. 2206–2213, 2004. View at Publisher · View at Google Scholar
  121. F. Haugen, A. Jorgensen, C. A. Drevon, and P. Trayhurn, “Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes,” FEBS Letters, vol. 507, no. 1, pp. 105–108, 2001. View at Publisher · View at Google Scholar · View at Scopus
  122. C. R. LaPensee, E. R. Hugo, and N. Ben-Jonathan, “Insulin stimulates interleukin-6 expression and release in LS14 human adipocytes through multiple signaling pathways,” Endocrinology, vol. 149, no. 11, pp. 5415–5422, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. D. G. Haider, G. Schaller, S. Kapiotis, C. Maier, A. Luger, and M. Wolzt, “The release of the adipocytokine visfatin is regulated by glucose and insulin,” Diabetologia, vol. 49, no. 8, pp. 1909–1914, 2006. View at Publisher · View at Google Scholar · View at Scopus